Syndax Pharmaceuticals, Inc.
General ticker "SNDX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
Syndax Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 37.8%.
Estimated limits based on current volatility of 2.8%: low 19.09$, high 20.18$
Factors to consider:
- Total employees count: 270 (+46.7%) as of 2024
- Top business risk factors: Operational and conduct risks, Product commercialization failure, Insufficient funding, Intellectual property risks, Manufacturing risks
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.66$, 18.78$]
- 2025-12-31 to 2026-12-31 estimated range: [6.69$, 16.33$]
Financial Metrics affecting the SNDX estimates:
- Negative: with PPE of -3.5 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -24.70 <= 0.33
- Positive: 18.93 < Shareholder equity ratio, % of 39.75 <= 41.86
- Negative: 0.01 < Interest expense per share per price, % of 0.44
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Negative: negative Industry operating cash flow (median)
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
Short-term SNDX quotes
Long-term SNDX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $23.68MM |
| Operating Expenses | $151.76MM | $229.95MM | $363.35MM |
| Operating Income | $-151.76MM | $-229.95MM | $-339.67MM |
| Non-Operating Income | $2.42MM | $20.59MM | $20.91MM |
| Interest Expense | $3.14MM | $0.21MM | $4.93MM |
| R&D Expense | $118.50MM | $163.03MM | $241.65MM |
| Income(Loss) | $-149.34MM | $-209.36MM | $-318.76MM |
| Profit(Loss)* | $-149.34MM | $-209.36MM | $-318.76MM |
| Stockholders Equity | $467.45MM | $554.20MM | $288.12MM |
| Inventory | $0.00MM | $0.00MM | $0.37MM |
| Assets | $497.24MM | $612.88MM | $724.82MM |
| Operating Cash Flow | $-133.68MM | $-160.60MM | $-274.90MM |
| Capital expenditure | $0.23MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-186.19MM | $117.61MM | $-219.78MM |
| Financing Cash Flow | $172.25MM | $264.13MM | $353.37MM |
| Earnings Per Share** | $-2.46 | $-2.98 | $-3.72 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.